Obsidian Therapeutics Inc(OBX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 0.09 | EPS (ttm) | 161.87 | Insider Own | 12.4% | Shs Outstand | 61.8M | Perf Week | 14.26% |
| Market Cap | 0.86B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 54.1M | Perf Month | -8.65% |
| Enterprise Value | 1.16B | PEG | - | EPS next Q | -0.52 | Inst Own | 21.65% | Short Float | 1.63% | Perf Quarter | -20.34% |
| Income | 0.12B | P/S | - | EPS this Y | - | Inst Trans | 13.15% | Short Ratio | 2.4 | Perf Half Y | -30.3% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 79.31% | ROA | 432.24% | Short Interest | 0.88M | Perf YTD | 216.82% |
| Book/sh | -2701.52 | P/C | 25 | EPS past 3/5Y | - | ROE | - | 52W High | -72.1% ($49.97) | Perf Year | 203.04% |
| Cash/sh | 0.56 | P/FCF | - | Sales past 3/5Y | - | ROIC | 397.65% | 52W Low | 310% ($3.40) | Perf 3Y | -69.31% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 469.96% | Gross Margin | - | Volatility(W/M) | 8.57% 10.34% | Perf 5Y | -96.17% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 1.4 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.3 | EPS Q/Q | -10780.55% | Profit Margin | - | RSI (14) | 49.26 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.3 | Sales Q/Q | - | SMA20 | 6.83% ($13.05) | Beta | 3.17 | Target Price | $39 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/08/12 | SMA50 | -12.11% ($15.86) | Rel Volume | 0.47 | Prev Close | $13.93 |
| Employees | 3 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -4.89% - | SMA200 | -0.18% ($13.97) | Avg Volume(3M) | 0.37M | Price | $13.94 |
| IPO | 2019/11/7 | Option/Short | No/Yes | Trades | 1425 | Volume | 174,494 | Change | 0.07% |
🧬 This is a US clinical-stage biotech company developing cell therapies that arm immune cells harvested from tumors with controllable cytokines. Its lead candidate, based on autologous tumor-infiltrating lymphocytes (TILs), is currently in clinical trials for melanoma and non-small cell lung cancer, and the company internally holds a synthetic biology platform for modulating protein function.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
OBX earns at a steady pace
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +79.3% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $9. Peers typically go for $920.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -96.2%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 21.6%.
Tap to view numbers
It ranks #171 of 594 in the industry
Based on market cap of $861M.
KURA#169 Kura Oncology Inc $877M PER - 
ANRO#170 Alto Neuroscience Inc $871M PER - OBX#171 Obsidian Therapeutics Inc $861M PER 0.1 
IVA#172 Inventiva ADR $857M PER - 
ABUS#173 Arbutus Biopharma Corp $834M PER 5.4 
FAQ
What kind of company is OBX?
OBX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of OBX?
The market cap of OBX is approximately $861M, ranking 2,687 within its sector.
What is the P/E ratio of OBX?
OBX has a P/E ratio of approximately 0.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OBX?
OBX has recorded a 52-week high of $49.97 and a low of $3.40.
